|
Video: What is a Stock Split?
|
|
Rocket Pharmaceuticals is a biotechnology company focused on the development of gene therapies for rare and devastating diseases. Co. has various clinical-stage ex vivo lentiviral vector programs. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. In the U.S., Co. has a clinical stage in vivo adeno-associated virus program for Danon disease. According to our RCKT split history records, Rocket Pharmaceuticals has had 1 split. | |
|
Rocket Pharmaceuticals (RCKT) has 1 split in our RCKT split history database. The split for RCKT took place on January 05, 2018. This was a 1 for 4 reverse split, meaning for each 4 shares of RCKT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Rocket Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the RCKT split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Rocket Pharmaceuticals shares, starting with a $10,000 purchase of RCKT, presented on a split-history-adjusted basis factoring in the complete RCKT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/19/2015 |
|
End date: |
03/18/2024 |
|
Start price/share: |
$24.20 |
|
End price/share: |
$26.52 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
9.59% |
|
Average Annual Total Return: |
1.01% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,955.35 |
|
Years: |
9.08 |
|
|
|
Date |
Ratio |
01/05/2018 | 1 for 4 |
|
|